De-escalating treatment for HPV-positive throat cancer with low-risk signals
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This Phase 2 trial tests whether people with HPV-positive oropharyngeal (throat) cancer who look “lower risk” can safely receive less intensive treatment. It uses HPV blood test results and cancer staging scans to guide whether treatment can be de-escalated.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed squamous cell cancer in the oropharynx (tonsil, base of tongue, soft palate, or back of throat).
- Your cancer must be HPV-related: either tumor tissue tests positive for p16 (over 70% staining) or—if no tissue block is available—an approved blood/tissue approach is used.
- Your HPV blood test (ctHPV DNA, using the Naveris report) must be detectable at screening (or at baseline if your primary site wasn’t biopsied).
- Your scans must show early-to-mid stage (T1–T3, N1–N2b) with no spread to distant organs, and no lymph node disease below the collarbone.
- You can’t have had major prior cancer treatments that overlap with this study (no prior chemotherapy for this cancer, and no prior overlapping radiation), and you can’t have had a cisplatin allergy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving less radiation along with chemotherapy is safe and effective for people with HPV-positive throat cancer. It aims to reduce side effects while still controlling the cancer.
This trial tests whether giving less radiation (while using standard chemotherapy) can treat HPV-related throat cancer effectively. It may help reduce radiation exposure while still controlling the cancer.
This trial tests whether a less intense (lower-dose) radiation plan, combined with chemotherapy, can control HPV-positive oropharyngeal (throat) cancer with fewer side effects. It targets people considered “low-risk” based on tumor size and lymph node involvement.
This trial tests whether we can safely use lower doses of radiation for people with HPV-related throat cancer, while still targeting the areas that need it. The goal is to reduce side effects without lowering the chance of a cure.
This trial tests whether using a de-escalated (lower/intensity-reduced) radiation approach can treat HPV-positive oropharyngeal squamous cell carcinoma. It may help reduce side effects while still keeping the cancer under control.
This trial tests a lower dose of radiation to certain neck areas for people with HPV-related oropharyngeal cancer. The goal is to see if reducing radiation can cause fewer side effects while still curing the cancer.
Hear when a new Oropharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.